Initial Early Access Experience with the Novel Anti-Epileptic Drug, Cenobamate, in an Adult Tertiary Referral Centre
Abstract number :
V.077
Submission category :
7. Anti-seizure Medications / 7E. Other
Year :
2021
Submission ID :
1826351
Source :
www.aesnet.org
Presentation date :
12/9/2021 12:00:00 PM
Published date :
Nov 22, 2021, 06:53 AM
Authors :
niamh colleran, RGN, RNP, RANP - RSCI, Dublin Ireland; Annette Breen - Neurology Department Beaumont - RCSI, Dublin; Norman Delanty - Consultant Neurologist,, Neurology Department , Beaumont Dublin, RSCI, Dublin , Ireland; hany El Naggar - Neurology Department, Beaumont Dublin - RCSI, Dublin; Brenda Liggan - Neurology Department, Beaumont Hospital - RCSI, Dublin; Javier Pene Ceballos - NEurology Department , Beaumont Hospital Dublin - RSCI, Dublin IReland; Maire White - Neurology Department Beaumont - RCSI, Dublin; Peter Widdess Walsh - Neurology, Beaumont Hospital - RCSI, Dublin
Rationale: This study was compiled to review the early clinical experience of cenobamate made available as part of an early access programme at Beaumont Hospital, Dublin.
Methods: Eight adults aged 19 to 51 years with severe drug-refractory focal epilepsy (taking three or more anti-epileptic drugs) were identified for inclusion in this study, and the Epilepsy Electronic Patient Record (EPR) was used to obtain relevant phenotypic information. Titration of cenobamate started at 12.5 mg daily and the dose increased every 2 weeks to reach a target of 200mg daily. Six patients have reached their target, and two patients have recently been initiated on drug.
Results: 75% (n=3) of patients with focal aware seizures (FA) and 66% (n=4) of patients with FIA (focal impaired awareness seizures) are seizure free. Additionally, 43% (n=3) of patients with focal to bilateral tonic clonic seizures are seizure free. There was 50% reduction in FA and FIA seizures in the remaining 2 people. One patient with FIA seizures has seen no change in seizure frequency. One person experiences atonic seizures and is seizure free for 3 months. Tonic seizure experienced by one patient has seen a 50% reduction. Fatigue was the most common treatment related adverse event in 75% of patients (n=6).
Conclusions: Cenobamate has shown to be an effective adjunctive treatment and was well tolerated. It is a new and exciting option for treating patients with refractory epilepsy.
Funding: Please list any funding that was received in support of this abstract.: no funding required.
Anti-seizure Medications